Search

Search Constraints

You searched for: Author/Creator Erba, Harry P.

Search Results

1. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Issue 2 (28th January 2023)

2. Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. (March 2016)

3. Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. (18th November 2015)

4. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey*. Issue 11 (2nd November 2018)

5. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine‐treated patients with myelodysplastic syndromes. (9th April 2014)

6. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry. Issue 1 (30th June 2020)

7. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry. Issue 1 (30th June 2020)

8. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry. Issue 1 (30th June 2020)

9. Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Issue 1 (2nd January 2023)